Brands: Coreg · Carvedilol
Average across 71 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Bryant Ranch Prepack | repackager | 120 | SUPPLYING |
| A-S Medication Solutions | repackager | 46 | SUPPLYING |
| Advagen Pharma Ltd | unknown | 28 | SUPPLYING |
| Proficient Rx LP | repackager | 26 | SUPPLYING |
| NuCare Pharmaceuticals,Inc. | repackager | 22 | SUPPLYING |
| Glenmark Pharmaceuticals Inc., USA | generic | 20 | SUPPLYING |
| Preferred Pharmaceuticals Inc. | repackager | 20 | SUPPLYING |
| Dr.Reddy's laboratories Limited | unknown | 20 | SUPPLYING |
| Northwind Health Company, LLC | repackager | 19 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 16 | SUPPLYING |
| Aphena Pharma Solutions - Tennessee, LLC | repackager | 14 | SUPPLYING |
| PD-Rx Pharmaceuticals, Inc. | repackager | 13 | SUPPLYING |
| Zydus Pharmaceuticals USA Inc. | generic | 12 | SUPPLYING |
| Zydus Lifesciences Limited | generic | 12 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | generic | 8 | SUPPLYING |
+ 17 more labelers
Shortages, recalls, and registration changes attached to this drug concept.
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm — Recalling firm: The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories — Product was distributed nationwide within the United States.
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level. — Recalling firm: Glenmark Pharmaceuticals Inc., USA — Nationwide in the USA
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level. — Recalling firm: Glenmark Pharmaceuticals Inc., USA — Nationwide in the USA
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level. — Recalling firm: Glenmark Pharmaceuticals Inc., USA — Nationwide in the USA
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm — Recalling firm: Glenmark Pharmaceuticals Inc., USA — Nationwide within the USA
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm — Recalling firm: Glenmark Pharmaceuticals Inc., USA — Nationwide within the USA
CGMP Deviations — Recalling firm: Glenmark Pharmaceuticals Inc., USA — U.S. Nationwide
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit — Recalling firm: Glenmark Pharmaceuticals Inc., USA — U.S. Nationwide
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit — Recalling firm: Glenmark Pharmaceuticals Inc., USA — U.S. Nationwide
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit — Recalling firm: Glenmark Pharmaceuticals Inc., USA — U.S. Nationwide
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit — Recalling firm: Glenmark Pharmaceuticals Inc., USA — U.S. Nationwide
CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit. — Recalling firm: Glenmark Pharmaceuticals Inc., USA — Nationwide in the U.S
CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit. — Recalling firm: Glenmark Pharmaceuticals Inc., USA — Nationwide in the U.S
Failed Impurities/Degradation Specifications — Recalling firm: Aurobindo Pharma USA Inc. — Nationwide in the US
Presence of Foreign Tablets/Capsules; report of two Paroxetine tablets were found in the bottle — Recalling firm: Zydus Pharmaceuticals (USA) Inc — Nationwide in the US
Labeling; Label Mix-up; report received of one bottle labeled as Acyclovir Tablets USP 400 mg actually contained Carvedilol Tablets 6.25 mg — Recalling firm: Zydus Pharmaceuticals USA Inc — Nationwide
Presence of Foreign Tablets/Capsules: Customer complaint for a small, solid, light yellow substance, identified as a fragmented tablet of another drug product, found mixed with tablets in a bottle of Carvedilol tablets 3.125mg. — Recalling firm: Zydus Pharmaceuticals USA Inc — Nationwide in the USA
